Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Elimination of HCV and emergence of steatotic liver disease among people who inject drugs living with and without HIV

Award Number: R01DA048063
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/15/2019
PERIOD OF PERFORMANCE END DATE: 02/28/2031

Group Awards By:

View Award Description

Elimination of HCV and emergence of steatotic liver disease among people who inject drugs living with and without HIV - Project Summary The purpose of the competing renewal of R01DA048063 is to investigate the incidence, causes, and dynamics of liver disease among persons who inject drugs (PWID) and those living with HIV (PWH). There is a high prevalence of HCV among PWID and HIV adversely affects all the disease stages. Consequently, liver cirrhosis incidence was steadily rising among PWID, especially PWH. In 2015, curative HCV treatments first became available and led to calls in the US and worldwide to eliminate HCV. Curative HCV treatments are reaching some Baltimore PWID and reducing the incidence of cirrhosis. However, too few were cured to reduce transmission in the community. New infections continue even among persons previously cured and threaten elimination goals. In addition, there is a high burden of steatotic liver disease (SLD) among Baltimore PWID. This finding corresponds with a national epidemic of SLD, which now has replaced HCV as the leading cause for liver failure/transplantation for persons >65 and women. Additional research is now urgently needed on HCV and liver disease. The factors that drive new HCV infections and prevent HCV treatment update must be revealed to inform public health policies. Likewise, the causes and consequences of SLD need to be studied in PWID with and without HIV infection. This fundamental epidemiological science is urgently required to understand trends and inform public health solutions to achieve the national goal of HCV elimination.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $675,160 )
2026	2026	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	001	6	4/27/2026	COMPETING CONTINUATION	$675,160
2026	2026	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	002	6	5/14/2026	COMPETING CONTINUATION	$0
2026	2023	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	000	5	1/30/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $675,160

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2023	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	000	5	2/28/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $687,581 )
2023	2023	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	000	5	12/15/2022	NON-COMPETING CONTINUATION	$618,824
2023	2023	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	001	5	1/27/2023	NON-COMPETING CONTINUATION	$68,757
														Subtotal = $687,581

Issue Date FY: 2022 ( Subtotal = $687,760 )
2022	2022	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	001	4	3/18/2022	NON-COMPETING CONTINUATION	$68,776
2022	2022	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	000	4	12/22/2021	NON-COMPETING CONTINUATION	$618,984
														Subtotal = $687,760

Issue Date FY: 2021 ( Subtotal = $664,100 )
2021	2021	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	000	3	12/16/2020	NON-COMPETING CONTINUATION	$597,689
2021	2021	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	001	3	2/19/2021	NON-COMPETING CONTINUATION	$66,411
														Subtotal = $664,100

Issue Date FY: 2020 ( Subtotal = $708,571 )
2020	2020	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	001	2	2/10/2020	NON-COMPETING CONTINUATION	$70,857
2020	2020	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	000	2	12/18/2019	NON-COMPETING CONTINUATION	$637,714
														Subtotal = $708,571

Issue Date FY: 2019 ( Subtotal = $727,804 )
2019	2019	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	000	1	1/10/2019	NEW	$727,804
														Subtotal = $727,804

Grand Total All Awards = $4,150,976

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Elimination of HCV and emergence of steatotic liver disease among people who inject drugs living with and without HIV

Award Number: R01DA048063

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/15/2019

PERIOD OF PERFORMANCE END DATE: 02/28/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer